Grifols SA (GRFS) Form 6-K — Nov 2, 2026
Grifols reported Q3 2026 revenue of EUR 2,040 million, up 8.4% at constant currency, with net profit up 28% to EUR 162 million and adjusted EBITDA of EUR 538 million at a 26.4% margin, driven by strong Biopharma and immunoglobulin demand. Immunoglobulins grew 11.3% cc in the quarter (SCIG up 40.3%), while albumin declined 13.2% cc due to China regulatory restrictions and elevated channel inventory; management is shifting sales to Tier 2 hospitals and retail pharmacies with partner Shanghai RAAS.
Key figures
- Eps
- 0
- Revenue
- 5614000000
- Net Income
- 162000000
- Total Debt
- Net financial debt per credit agreement EUR 7,706 million
- Revenue Yoy
- 9M'26 +4.6% cc; Q3'26 +8.4% cc to EUR 2,040 million
- Cash Position
- 486000000
- Liquidity eur m
- 2140
- Q3 revenue eur m
- 2040
- Net leverage ratio
- 3.98x
- Fcf pre ma q3 eur m
- 208
- Ig growth q3 cc pct
- 11.3
- Fcf pre ma ytd eur m
- 298
- Ytd net profit eur m
- 390
- Scig growth q3 cc pct
- 40.3
- Adjusted ebitda q3 eur m
- 538
- Egypt liters target 2029
- 3000000
- Adjusted ebitda ytd eur m
- 1392
- Albumin decline q3 cc pct
- -13.2
- Ytd net profit growth pct
- 28.4
- Biopharma growth q3 cc pct
- 10.3
- Adjusted ebitda margin q3 pct
- 26.4
- Adjusted ebitda margin ytd pct
- 24.8
- Interim dividend per share eur
- 0.15
- Egypt plasma liters 2026 target
- 1000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.